Pfizer has announced a strategic shift towards focusing on protein-based drugs within its cancer portfolio, moving away from its traditional development of small molecule pills. This decision comes at a time when Pfizer's stock ($PFE) has hit near its lowest point in over a decade, attributed to the collapse of its COVID-19 business. Analysts and investors, stating 'IMO', suggest that for Pfizer to recover, it needs to showcase a megablockbuster drug akin to Keytruda, rather than relying on a broad array of molecules that may not seem immediately significant. Despite the current downturn, some market watchers, including those long on Pfizer stock, believe it represents one of the best risk vs reward opportunities in the US stock market.
IMO $PFE needs to show they have one megablockbuster drug like Keytruda. Not an armada of molecules that - from the first impression perspective - look meaningless (wrongly). If so, the stock would quickly recover. I'm long $PFE btw. https://t.co/9tJeoHdsVf
IMO $PFE needs to show they have one megablockbuster drug like Keytruda. Not an armada of molecules that - in first hand- look meaningless (wrongly). If so, the stock would quickly recover. I'm long $PFE btw. https://t.co/9tJeoHdsVf
IMO $PFE needs to show they have one megacblockbuster drug like Keytruda. Not an armada of molecules that - in first hand- look meaningless (wrongly). If so, the stock would quickly recover. I'm long $PFE btw. https://t.co/9tJeoHdsVf
IMO $PFE needs to show they have one megacblockbuster drug like Keytruda. Not an armada of molecules that don't look (wrongly) not attractive. If so, the stock would quickly recover. https://t.co/9tJeoHdsVf
With the collapse of its covid business, Pfizer stock has collapsed to near its lowest point in 10+ years. Good epidemiological news is bad news for Pfizer. https://t.co/9rJxuldHxv
With the collapse of its covid business, Pfizer stock has collapsed to its lowest point in 10+ years. Good epidemiological news is bad news for Pfizer. https://t.co/AZB4v5JIME
$PFE is one of the best opportunities in the entire US stock market in terms of risk vs reward. via @Downtown https://t.co/tur5MHRCcR
Pfizer says it will focus on drugs in its cancer portfolio that are based on proteins, not small molecule pills as it has traditionally developed. https://t.co/Yq1mgWhU5A